Q4 2024 Oncopeptides AB Earnings Call Transcript
Key Points
- Oncopeptides AB (FRA:OND) reported a 35% increase in European sales in Q4 compared to Q3, indicating positive sales momentum.
- The company has secured regional access in Spain and reached an agreement with the Italian medicine's agency for pricing and reimbursement, paving the way for sales growth in these markets.
- Oncopeptides AB (FRA:OND) is advancing in Japan with regulatory alignment and is in advanced negotiations for a licensing deal, which could have significant financial impact.
- The company has a strong cash position of SEK179 million, aligning with plans to achieve cash flow positivity by the end of 2026.
- Positive real-world experience data from the US market supports the efficacy and safety of their product, enhancing market confidence.
- Despite growth, Oncopeptides AB (FRA:OND) is not yet at the desired level of sales, indicating room for improvement.
- The company faces challenges in market access in France, where reimbursement for their product was advised against.
- R&D expenses increased in Q4 due to one-off costs, impacting overall financial performance.
- The company relies on concluding additional business development partnerships to achieve cash flow positivity, adding uncertainty to financial projections.
- Market access negotiations in Norway are ongoing and challenging, potentially delaying sales in that region.
Hi, everyone, and welcome to this presentation of our year-end report of 2024. This is our standard disclaimer. I am Sofia Heigis, CEO of Oncopeptides, and with me I have Henrik Bergentoft who will give a financial update later.
First, I will go through some of the key highlights of the 4th quarter and the beginning of 2025. Revenue in Q4 was SEK9.9 million, and while we are still not at the level of sales where we would want to be, we are encouraged by a 35% increase of Europeans saves in Q4 versus Q3. The cash position was SEK179 million by the end of the year, and we remain on track for cash flow positivity towards the end of 2026.
The promising start we saw in Spain continued into Q4 and we have now secured regional access to ensure we can deliver on our financial projections for Spain in 2025. Germany was a major contributing market to our reported growth. We have seen a strong increase in momentum during the last few weeks of Q4 and in the beginning of 2025, which support our confidence in that we have reached a new level of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
